Global trade and access to medicines: AIDS treatments in Thailand

Lancet

Volumn 354, Issue 9193, 1999, Pages 1893-1895

  Wilson, David ^a   Cawthorne, Paul ^a   Ford, Nathan ^a   Aongsonwang, Saree ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIVIRUS AGENT; DIDANOSINE; FLUCONAZOLE; GENERIC DRUG; INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG QUALITY; FUNGAL MENINGITIS; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MARKET; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH; THAILAND; VERTICAL TRANSMISSION;

EID: 0033610727     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)06114-0     Document Type: Note

References (19)

1. Human Development report. 1999;United Nations Development Programme, London.
2. Globalization and Access to Drugs: implications of the WTO/TRIPS agreement/WHO/DAP.98.9. 1997;WHO, Geneva.
3. Revised Drug Strategy: Resolution WHO 52.19, 52nd World Health Assembly. Geneva: WHO, 1999.
4. Correa C. The Uruguay round and drugs. 1997;WHO, Geneva.
5. Overview of satelite symposium 21: formulating national use of antiretrovirals in Thailand. Proceedings of the Third International Conference on AIDS in Asia and the Pacific, Chiang Mai, Thailand, Sept 17-21, 1995: 88-98.
6. Kunanusont C, Phoolcharoen W, Rojanapitayakorn W. The preliminary report on formulating rational use of anti-retrovirals in Thailand. In: HIV/AIDS in Thailand 1996: Adults & Pediatrics. Bangkok: Infectious Disease Association of Thailand, 1996: 82-97.
7. Guidelines for the clinical management of HIV infection in Children/adults, 5th edn. 1997;Ministry of Public Health, Nonthaburi.
8. Shaffer N., Chuachoowong R., Mock P.A.et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet. 353:1999;773-780.
9. Suwanjandee J., Wilson D. Helsinki Declaration and Thailand. Lancet. 354:1999;343.
10. Hemachudha T., Mitrabhakdi E., Wilde H.et al. Additional reports of failure to respond to treatment after rabies exposure in Thailand. Clin Infect Dis. 28:1999;143-144.
11. Shakoor O., Taylor R., Behrens R. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health. 2:1997;839-845.
12. Thai drug system: a situation analysis for further development. 1995;Thai Food and Drug Administration, Bangkok.
13. Lomar A. Custos directos do tratimento da AIDS no Brasil. 1999;Fundacao Insituto de Pesquisas Economica/Ministerio da Saude, Sao Paulo.
14. US code of regulations on exclusive licensing of government owned interventions: section 404.7. Washington, DC: US Government Printing Office, 1987.
15. The US Government position on compulsory licensing of patents. 1999;US Patent and Trademark Office, Geneva.
16. Thailand Country Report: 2nd Quarter 1998. 1999;EIU, London.
17. Aongsonwang S. Pharmaceutical patent law: a law by trans-national companies - Thailand's experience. Paper presented at NGO meeting on compulsory licensing of essential medical technologies. 1999.
18. Office of the United States Trade Representative national trade estimate report on foreign trade barriers. Washington DC: US Trade Representative, 1999.
19. McGregor A., Compulsory drug licensing for countries hit by H.I.V. is mooted. Lancet. 353:1999;1165.